Should make no difference if approved under AA pathway.
Exclusivity is a period of time when an approved brand-name drug is protected from generic drug competition. We fall under 'New Clinical Investigation Exclusivity' where a 3-year period of exclusivity is granted for a drug product that contains an active moiety that has been previously approved.
Paul Rennie interviewed on Marcus Today Podcast., page-9
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.015(7.32%) |
Mkt cap ! $78.73M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 22.5¢ | 21.0¢ | $186.1K | 847.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 167858 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 86321 | 5 |
View Market Depth
| Last trade - 14.42pm 04/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |